Antiviral Peptides
3 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- EnfuvirtideEnfuvirtide is a synthetic 36‑amino‑acid peptide approved as a fusion inhibitor for the treatment of HIV‑1 infection. It is administered by subcutaneous injection, typically twice daily, and is used in combination with an optimised background antiretroviral regimen. Clinical trials in adults and children have shown that enfuvirtide reduces plasma HIV‑RNA levels and increases CD4+ T‑cell counts, particularly in patients with multidrug‑resistant virus or limited treatment options.
- JE-2147JE-2147 (also known as AG‑1776, KNI‑764) is an experimental dipeptide HIV‑1 protease inhibitor belonging to the allophenylnorstatine (APNS) family. Developed as a second‑generation protease inhibitor, it shows picomolar binding affinity for HIV‑1 protease and retains activity against a wide range of wild‑type and multi‑protease‑inhibitor‑resistant HIV strains in vitro. Research is ongoing to improve its pharmacokinetic profile and to explore potential repurposing against other viral proteases such as SARS‑CoV‑2 Mpro.
- Peptide-TPeptide‑T (also called D‑Ala‑Peptide T‑amide or DAPTA) is an investigational peptide derived from the HIV‑1 envelope that has been explored as an immunomodulatory agent, notably for HIV‑associated dementia. It is studied in research settings via intranasal, intravenous or subcutaneous delivery, but it has not received regulatory approval for any indication.